KTTA - Pasithea Therapeutics Corp.
Previous close
2.79
-0.090 -3.226%
Share volume: 200
Last Updated: Thu 26 Dec 2024 08:13:21 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.88
-0.09
-3.13%
Fundamental analysis
14%
Profitability
6%
Dept financing
2%
Liquidity
75%
Performance
10%
Performance
5 Days
-2.96%
1 Month
-14.24%
3 Months
-55.88%
6 Months
-51.02%
1 Year
-70.19%
2 Year
-77.65%
Key data
Stock price
$2.79
DAY RANGE
$2.57 - $2.88
52 WEEK RANGE
$2.66 - $9.25
52 WEEK CHANGE
-$66.91
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Tiago R. Marques
Region: US
Website: pasithea.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: pasithea.com
Employees: 3
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Pasithea Therapeutics Corp. engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.
Recent news